Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beijing Attracts Billion-Yuan Investment For Health Care Projects

This article was originally published in PharmAsia News

Executive Summary

To accelerate the development of the biopharmaceutical industry, Beijing Municipal Bureau of Industrial Development is stepping up efforts to provide investors with policy consulting and tracking services. The city has this year signed up eight major health care investments totaling 3.83 billion yuan ($548 million). The projects comprise: (1) joint production of MMR (measles, mumps and rubella) vaccines by GSK and Xili Pharmaceutical Group; (2) Genzyme Biotech Beijing's R&D and laboratory production project; (3) Kaizheng Biotech's human blood substitutes and new drug R&D production base; (4) Xiuzheng Pharmaceutical Group's industrial park; (5) Korean Daewoong Pharmaceutical's R&D center and production base; (6) Tiandao Biotech's monoclonal antibody R&D and production base; (7) Mindray's Beijing academic institution; and (8) Genova Biotech's Novaferon production base. (Click here for more - Chinese language)

You may also be interested in...

Korean Daewoong Pharmaceutical Opens R&D Center in India

SEOUL - South Korea's Daewoong Pharmaceutical opened a new research and development center Jan. 20 in the southern India city of Hyderabad as it tries to pave the way for the development of what it called "different generics" and new brand products for the U.S. and European markets

Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts